Bloomberg Audio Studios, Podcasts, radio news.
The Stock Movers Report, your roundup of companies making moves in the stock market, harnessing the power of Bloomberg Data.
That's two stock movers. This the podcast. You gotta start with JP Morgan.
Right, No, no, we're not because it's not moving as much. So we decided, you know what we're going, Jamie Morgan. We're going to go to Delta Airlines because that is moving and it's pretty actually saying the wrong direction. I wanted to get some movers in here, so it's ticker d AL. They're beefing up their fleet, right. They ordered about thirty Boeing seven eighty seven Dreamliner jets. It's actually the first ever purchase for that model for the company.
But here's the thing. It also reported a beat on fourth court earnings, revenue rising to a record fifty eight point three billion dollars. But the thing is it's annual profit outlook it underwhelmed a DELSA said it It also predict a free cash flow about three billion to four billion, and that was less than the four point six million that it pulled in last year, and that's why its
shares are lower. They've been down as much as six percent, and then it's also dragging down shairs of American Airlines and United on top of it. So that was Delta Airlines. I want to move on to this company called L three Harris Technologies as ticker LHS, their shares gaining thirteen percent. The US Department Defense they basically set to invest in the company's missile unit, a one billion dollar convertible preferred security.
They called it a first of its kind partnership. They said it's going to increase capacity to build solid rocket motors for US missiles. But I mean it came after you know, Defense Secretary Peak Hegseth. He wants the speed innovation. They've been talking about this really.
Really interesting potential transaction. A family member worked for EL three Harris for a while and it's like wicked, sophisticated, secret, secret, triple top secret stuff, you know.
Interesting.
But they they're using these tightening links though between the government a major you know, defense contract.
It's a new thing.
Mockey Martin, we've seen it. Okay, last one. I'll do a quick mention biotech firm Traverse Therapeutics tv TX. They're slumping as much as twenty eight percent yet received a request from the FDA. They want to clarify that clinical benefit of its therapy it treats we are kidney disease and answer saying, you know what, it could delay the approval by the agency, So that's what they're worried about.
The Stock Movers report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street and for the latest market moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business app.